scholarly journals Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study

2021 ◽  
Vol Volume 13 ◽  
pp. 3551-3560
Author(s):  
Jin-Kai Feng ◽  
Ju-Xian Sun ◽  
Zong-Han Liu ◽  
Jing-Wen Gu ◽  
Zhen-Hua Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cohort Study ◽  
Bile Duct ◽  
Real World ◽  
Retrospective Cohort Study ◽  
Transarterial Chemoembolization ◽  
Retrospective Cohort ◽  
Tumor Thrombus ◽  
Efficacy And Safety ◽  
Bile Duct Tumor

scholarly journals Incorporation of biochemical factors for survival analysis of transarterial chemoembolization in patients with hepatocellular carcinoma: A retrospective cohort study

2019 ◽  
Vol 47 (10) ◽  
pp. 4862-4871
Author(s):  
Wen-Hui Chan ◽  
Song-Fong Huang ◽  
Chao-Wei Lee ◽  
Tsung-Han Wu ◽  
Kuan-Tse Pan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Transarterial Chemoembolization ◽  
Retrospective Cohort ◽  
Cox Regression ◽  
Long Term Outcomes ◽  
Cox Regression Analysis ◽  
The Mean

Introduction Hepatocellular carcinoma (HCC) is a common gastrointestinal cancer that occurs worldwide, and conventional transarterial chemoembolization (cTACE) is one of the first treatment choices for advanced HCC. However, biochemical factors and comorbidity have seldom been reported in the long-term outcomes. Methods This retrospective cohort study included 444 HCC patients who underwent cTACE-based therapy in 2010 to 2012. Survival outcomes were analyzed using a Kaplan–Meier curve and Cox regression analysis. Results The mean age was 62.1 ± 12.5 years, and 74.3% were men. Analysis of the mean biochemical values indicated that the presence of portal vein thrombosis, α-fetoprotein (AFP) >200 ng/mL, AJCC 7th stage III, diabetes, albumin <3 g/dL, and hemoglobin were significantly and independently associated with poorer long-term outcomes. Discussion The presence of venous thrombus and elevation of AFP levels are the most important factors in cTACE treatment. The host factors, including metabolic status and liver damage, should be evaluated in these patients.

Sign in / Sign up

Export Citation Format

Share Document